...
首页> 外文期刊>Biomaterials >Antibiotic-loaded, silver core-embedded mesoporous silica nanovehicles as a synergistic antibacterial agent for the treatment of drug-resistant infections
【24h】

Antibiotic-loaded, silver core-embedded mesoporous silica nanovehicles as a synergistic antibacterial agent for the treatment of drug-resistant infections

机译:载有抗生素的,银包埋的介孔二氧化硅纳米载体作为协同抗菌剂,用于治疗耐药性感染

获取原文
获取原文并翻译 | 示例

摘要

Drug-resistant bacterial infections have become one of the most serious risks in public health as they make the conventional antibiotics less efficient. There is an urgent need for developing new generations of antibacterial agents in this field. In this work, a nanoplatform of LEVO-loaded and silver core embedded mesoporous silica nanovehicles (Ag@MSNs@LEVO) is demonstrated as a synergistic antibacterial agent for the treatment of drug-resistant infections both in vitro and in vivo. The combination of the inner Ag core and the loaded antibiotic drug in mesopores endows the single-particle nanoplatform with a synergistic effect on killing the drug-resistant bacteria. The nanoplatform of Ag@MSNs@LEVO exhibits superior antibacterial activity to LEVO-loaded MSNs (MSNs@LEVO) and silver core-embedded MSNs (Ag@MSNs) in vitro. In the in vivo acute peritonitis model, the infected drug-resistant Escherichia coli GN102 in peritoneal cavity of the mice is reduced by nearly three orders of magnitude and the aberrant pathological feature of spleen and peritoneum disappears after treatment with Ag@MSNs@LEVO. Importantly, this nanopaltform renders no obvious toxic side effect to the mice during the tested time. There is no doubt that this study strongly indicates a promising potential of Ag@MSNs@LEVO as a synergistic and safety therapy tool for the clinical drug-resistant infections. (C) 2016 Elsevier Ltd. All rights reserved.
机译:耐药细菌感染已使传统抗生素的效力降低,已成为公共卫生中最严重的风险之一。在该领域迫切需要开发新一代的抗菌剂。在这项工作中,LEVO负载和银芯嵌入的介孔二氧化硅纳米载体(Ag @ MSNs @ LEVO)的纳米平台被证明是一种协同抗菌剂,可用于体内外治疗耐药性感染。内银核和中孔中加载的抗生素药物的结合赋予了单颗粒纳米平台杀灭耐药细菌的协同作用。 Ag @ MSNs @ LEVO的纳米平台在体外具有比LEVO负载的MSNs(MSNs @ LEVO)和银芯嵌入式MSNs(Ag @ MSNs)更好的抗菌活性。在体内急性腹膜炎模型中,用Ag @ MSNs @ LEVO治疗后,小鼠腹膜腔中被感染的耐药大肠杆菌GN102减少了近三个数量级,脾脏和腹膜的异常病理特征消失了。重要的是,在测试期间,这种纳米调色板对小鼠没有明显的毒副作用。毫无疑问,这项研究强烈表明Ag @ MSNs @ LEVO作为临床耐药性感染的协同和安全治疗工具的潜力很大。 (C)2016 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号